Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On May 15, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the first quarter of 2025 and provided a business update.</li><li>Following the approval of Zevaskyn (prademagene zamikeracel) by the U.S. Food and Drug Administration (FDA) for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), the company has activated the first qualified treatment center that will begin treating patients in the third quarter of 2025.</li><li>Since the approval of Zevaskyn, approximately 30 patients and caregivers have begun registering in the Abeona Assist patient services program.</li></ul>

On May 15, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the first quarter of 2025 and provided a business update.Following the approval of Zevaskyn (prademagene zamikeracel) by the U.S. Food and Drug Administration (FDA) for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), the company has activated the first qualified treatment center that will begin treating patients in the third quarter of 2025.Since the approval of Zevaskyn, approximately 30 patients and caregivers have begun registering in the Abeona Assist patient services program.

ABEO: Sells Priority Review Voucher for 155 Million 